Vorinostat (MK-0683, SAHA, Suberoylanilide Hydroxamic Acid, Suberanilohydroxamic Acid, Zolinza, CAS 149647-78-9), >99%

LC Laboratories' Product Number V-8477 - Vorinostat (MK-0683, SAHA, Suberoylanilide Hydroxamic Acid, Suberanilohydroxamic Acid, Zolinza, CAS 149647-78-9), >99% - for research use only. Vorinostat is a histone deacetylase inhibitor and causes growth arrest and death of some transformed cells both in vitro and in vivo, with little or no toxic effects on normal cells. Vorinostat was studied in single agent trials and combination trials for patients with refractory cutaneous T cell lymphoma. Vorinostat caused an accumulation of acetylated histones, p21(WAF1) and bax, a decrease of Stat6, and activation of caspase-3, and thus selectively induced malignant T cell apoptosis. Vorinostat improves tumor radioresponse. Vorinostat is the active ingredient in the drug sold under the trade name Zolinza®. This drug has been approved in at least one country for use in patients with cutaneous T cell lymphoma (CTCL) and Sézary syndrome, another type of lymphoma closely related to CTCL. NOTE: The vorinostat product sold by LC Laboratories is NOT Zolinza® and is NOT for human use.

• Supplier: LC Laboratories
• Product #: V-8477
• Sku #: V-8477_500mg